Floatz Rating
B58/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07012031CT.gov Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation | — | Recruiting | — | — | — |
NCT07543172CT.gov CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07563738CT.gov A 2-part Phase 1/2 Open-label Trial on ODM-212 | — | Recruiting | — | — | — |
NCT07143513CT.gov Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients | — | Completed | — | — | — |
NCT06068153CT.gov AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC | — | Withdrawn | — | — | — |
NCT06497556CT.gov A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT06333951CT.gov Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). | — | Active Not Recruiting | — | — | — |
NCT06582771CT.gov A Study of Sotorasib in People With Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06532149CT.gov ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer | — | Recruiting | — | — | — |
NCT06249282CT.gov Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
Show 22 more trialsShow fewer
NCT05815186CT.gov Ladarixin With Sotorasib in Advanced NSCLC - Phase II | — | Withdrawn | — | — | — |
NCT06333678CT.gov A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT05920356CT.gov A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | — | Recruiting | — | — | — |
NCT05815173CT.gov Ladarixin With Sotorasib in Advanced NSCLC | — | Recruiting | — | — | — |
NCT05631249CT.gov Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C | — | Recruiting | — | — | — |
NCT05374538CT.gov VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT05451056CT.gov An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib | — | Unknown | — | — | — |
NCT05400577CT.gov Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC | — | Withdrawn | — | — | — |
NCT05480865CT.gov SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation | — | Terminated | — | — | — |
NCT05180422CT.gov A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis | — | Withdrawn | — | — | — |
NCT05311709CT.gov Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities | — | Unknown | — | — | — |
NCT05074810CT.gov Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients | — | Active Not Recruiting | — | — | — |
NCT05398094CT.gov Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy | — | Recruiting | — | — | — |
NCT05313009CT.gov Tarlox and Sotorasib in Patients With KRAS G12C Mutations | — | Terminated | — | — | — |
NCT04933695CT.gov A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment | — | Completed | — | — | — |
NCT05054725CT.gov Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies | — | Completed | — | — | — |
NCT04959981CT.gov A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | — | Completed | — | — | — |
NCT04892017CT.gov Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors | — | Terminated | — | — | — |
NCT04625647CT.gov Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | — | Active Not Recruiting | — | — | — |
NCT04720976CT.gov JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04303780CT.gov Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). | — | Active Not Recruiting | — | — | — |
NCT04667234CT.gov Expanded Access of Sotorasib | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sotorasib (this asset) | National Cancer Institute (NCI) | P3 | B · 58 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Sotorasib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lung Cancer | — | P2 | BB · 64 |
| Colorectal Cancer | — | P3 | B · 59 |
| Breast Cancer | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sotorasib in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sotorasib-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →